A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, 14 which underpins the inflammatory response in moderate-to-severe plaque PsO ...

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.